Full Text Journal Articles by
Author Bradley G Somer

Advertisement

Find full text journal articles








The utilization and impact of adjuvant therapy following neoadjuvant therapy and resection of pancreatic adenocarcinoma: does more really matter?

Justin A Drake, Zachary E Stiles, Stephen W Behrman, Evan S Glazer, Jeremiah L Deneve, Bradley G Somer, Noam A Vanderwalde, Paxton V Dickson,

BACKGROUND:Although neoadjuvant therapy is increasingly administered to patients with pancreatic ductal adenocarcinoma (PDAC), the impact of additional adjuvant therapy (AT) following resection is not well defined. METHODS:The National Cancer Database (NCDB) was queried for patients who received neoadjuvant therapy followed by R0 or R1 resection for PDAC. Factors influencing survival, ... Read more >>

HPB (Oxford) (HPB : the official journal of the International Hepato Pancreato Biliary Association)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Treatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxel.

Arthur C Houts, Daniel Hennessy, Mark S Walker, Leonardo Nicacio, Stephen F Thompson, Paul Je Miller, Bradley G Somer,

Treatment for metastatic castrate-resistant prostate cancer in community settings is not well understood.To examine treatment patterns, sequencing, and outcomes in patients receiving second- and third-line treatment after first-line docetaxel.We used a community oncology database to identify patients who progressed after line 1 docetaxel (D) and received line 2 cabazitaxel (DC), ... Read more >>

J Community Support Oncol (The Journal of community and supportive oncology)
[2014, 12(9):321-328]

Cited: 2 times

View full text PDF listing >>



Advertisement

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

Jeffrey R Infante, Bradley G Somer, Joon Oh Park, Chung-Pin Li, Max E Scheulen, Saifuddin M Kasubhai, Do-Youn Oh, Yuan Liu, Suman Redhu, Klaudia Steplewski, Ngocdiep Le,

BACKGROUND: Trametinib, an oral mitogen/extracellular signal-related kinase (MEK)1/2 inhibitor, holds promise for malignancies with rat sarcoma (RAS) mutations, like pancreas cancer. This phase II study was designed to determine overall survival (OS) in patients with pancreas cancer treated with trametinib and gemcitabine. Secondary end-points included progression-free survival (PFS), overall response ... Read more >>

Eur. J. Cancer (European journal of cancer (Oxford, England : 1990))
[2014, 50(12):2072-2081]

Cited: 89 times

View full text PDF listing >>



A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer.

Paweł Wiechno, Bradley G Somer, Begoña Mellado, Piotr L Chłosta, José Manuel Cervera Grau, Daniel Castellano, Christoph Reuter, Michael Stöckle, Jörn Kamradt, Joanna Pikiel, Ignacio Durán, Steffen Wedel, Sophie Callies, Valérie André, Karla Hurt, Jacqueline Brown, Michael Lahn, Bernhard Heinrich,

Castration-resistant prostate cancer (CRPC) is partially characterised by overexpression of antiapoptotic proteins, such as survivin. In this phase 2 study, patients with metastatic CRPC (n=154) were randomly assigned (1:2 ratio) to receive standard first-line docetaxel/prednisone (control arm) or the combination of LY2181308 with docetaxel/prednisone (experimental arm). The primary objective was ... Read more >>

Eur. Urol. (European urology)
[2014, 65(3):516-520]

Cited: 20 times

View full text PDF listing >>



Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.

Lee S Schwartzberg, Grace Wang, Bradley G Somer, L Johnetta Blakely, Benton M Wheeler, Mark S Walker, Edward J Stepanski, Arthur C Houts,

BACKGROUND: In this phase II study, we explored efficacy and toxicity of combined endocrine and low-dose metronomic chemotherapy therapy consisting of fulvestrant and capecitabine in estrogen and/or progesterone receptor-positive, HER2-negative MBC. PATIENTS AND METHODS: Patients with ≤ 1 previous hormonal treatment in the metastatic setting received an injection fulvestrant loading dose ... Read more >>

Clin. Breast Cancer (Clinical breast cancer)
[2014, 14(1):13-19]

Cited: 12 times

View full text PDF listing >>



Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma.

Bradley G Somer, Donald E Tsai, Lisa Downs, Barry Weinstein, Stephen J Schuster, ,

Arthritis Rheum. (Arthritis and rheumatism)
[2003, 49(3):394-398]

Cited: 44 times

View full text PDF listing >>





Advertisement

Disclaimer
0.6322 s